Carroll Hospital Selects Faxitron’s LOCalizer™ for Use in Breast Lesion Localization Procedures

Innovative, patient-focused technology enabling precision and ease of
use revolutionizes breast surgery guidance

TUCSON, Ariz.–(BUSINESS WIRE)–Faxitron, a global leader in best-in-class digital specimen imaging
systems for breast cancer intervention and life science research, today
announced that Carroll Hospital, a private, nonprofit 193-bed hospital
located in Westminster, Maryland, has implemented LOCalizer™*,
a wireless radiofrequency identification (RFID) breast lesion
localization system. Leveraging the technology for all non-palpable
lumpectomy procedures, Carroll Hospital selected LOCalizer to enhance
the patient experience and make breast localization procedures easier
for surgeons and care teams, ultimately driving better overall care and
outcomes.

Standard methods of localization have historically involved wire hooks,
and more recently, radioactive seeds, to identify non-palpable breast
lesions for removal. While still used in many hospitals, these
approaches are encumbered by complex regulations and potential
complications, such as unintended wire or seed migration, patient
discomfort, logistical and workflow challenges, and added stress for
both patients and providers alike.

Since implementing LOCalizer in March 2018, Carroll Hospital has
experienced significant positive results leveraging the less-invasive
technology in nearly 25 surgeries. Non-radioactive, wireless RFID tags
marking the lesion enable the surgeon to pinpoint the location and
measure the exact distance to the lesion in millimeters. Additionally,
tags can be implanted in patients’ weeks prior to surgery eliminating
scheduling and logistical hurdles as well as significantly freeing up
staff members for patient care.

“As the first hospital in Maryland to adopt LOCalizer, we’re proud to
pioneer this innovative, new technology and take a significant step
forward in advancing breast cancer treatment with a patient-focused
solution that equally benefits the healthcare team,” said Dr. Dona
Hobart, Breast Surgeon and Medical Director of the Center for Breast
Health at Carroll Hospital. “With the added precision and depth made
possible with LOCalizer, we’re able to measure specimens with more
accuracy than ever before, and in turn, tailor surgery appropriately,
which is critical in delivering the exceptional level of care that our
patients deserve and expect.”

For more information about LOCalizer, visit Faxitron’s website at: https://www.faxitron.com/product/localizer/

About Carroll Hospital

Carroll Hospital, a LifeBridge Health center, is a nonprofit, acute care
facility offering the latest in medical technology, experienced medical
professionals in a variety of specialties and a continuum of programs
and services to meet the needs of the community.

About LOCalizer

LOCalizer is a wireless radiofrequency identification (RFID) breast
lesion localization system that uses the latest technology to help guide
surgical removal of non-palpable lesions.

The LOCalizer system includes a Tag Applicator, a miniature RFID Tag, a
handheld Reader and a single-use sterile Probe. The Tag is designed to
be implanted in the lesion up to 30 days before surgery, and is free of
radioactivity. The uniquely mobile handheld Reader contains an
integrated Loop Probe that can be used directly on the skin to determine
the location and distance to the lesion and plan the surgical path.
During an operation, a single-use sterile Surgical Probe can be used in
small incisions to help guide the surgeon directly to the lesion.

About Faxitron

As a global leader and pioneer for best-in-class digital imaging
systems, Faxitron is dedicated to helping healthcare providers and
researchers achieve their vision for a better, healthier world at large.
Through the continuous innovation and advancement of imaging
technologies, Faxitron aims to elevate the standard of care in medicine
and the standard of quality in life science research. With applications
spanning from breast surgery to pathology imaging, and from biological
irradiation and preclinical imaging to non-destructive testing, Faxitron
is building a comprehensive portfolio of solutions that sets new
standards for precision and quality in the industry. For more
information visit www.faxitron.com.

Contacts

MERGE Boston for Faxitron
Wyatt Avison
wavison@mergeworld.com